Advertisement

Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial

      Abstract

      Background

      In a randomized phase III trial in treatment-naive patients with metastatic renal cell carcinoma (RCC), axitinib versus sorafenib yielded numerically longer progression-free survival (median, 10.1 vs. 6.5 months; hazard ratio [HR], 0.77; 1-sided P = .038) and significantly higher objective response rate (32% vs. 15%; 1-sided P = .0006). In this article, we report overall survival (OS) and updated safety results.

      Patients and Methods

      Previously untreated patients with metastatic RCC (n = 288), stratified according to Eastern Cooperative Oncology Group performance status (ECOG PS; 0 vs. 1), were randomized 2:1 to receive axitinib 5 mg twice per day (b.i.d.; n = 192) or sorafenib 400 mg b.i.d. (n = 96).

      Results

      Median OS (95% confidence interval [CI]) was 21.7 months (18.0-31.7) with axitinib versus 23.3 months (18.1-33.2) with sorafenib (stratified HR, 0.995; 95% CI, 0.731-1.356; 1-sided P = .4883). Among patients with ECOG PS of 0, median OS was numerically longer with axitinib than with sorafenib (41.2 vs. 31.9 months; HR, 0.811, 1-sided P = .1748), whereas among patients with ECOG PS 1, median OS was shorter with axitinib than with sorafenib (14.2 vs. 19.8 months; HR, 1.203; 1-sided; P = .7973). Incidence and severity of common adverse events were consistent with previous reports.

      Conclusion

      OS was similar between axitinib and sorafenib in treatment-naive patients with metastatic RCC, and no new safety signals emerged.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hu-Lowe D.D.
        • Zou H.Y.
        • Grazzini M.L.
        • et al.
        Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
        Clin Cancer Res. 2008; 14: 7272-7283
        • Hutson T.E.
        • Lesovoy V.
        • Al-Shukri S.
        • et al.
        Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
        Lancet Oncol. 2013; 14: 1287-1294
        • Motzer R.J.
        • Escudier B.
        • Bukowski R.
        • et al.
        Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.
        Br J Cancer. 2013; 108: 2470-2477
        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 27: 3584-3590
        • Motzer R.J.
        • Hutson T.E.
        • Cella D.
        • et al.
        Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
        N Engl J Med. 2013; 369: 722-731
        • Motzer R.J.
        • Nosov D.
        • Eisen T.
        • et al.
        Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
        J Clin Oncol. 2013; 31: 3791-3799
        • Sternberg C.N.
        • Hawkins R.E.
        • Wagstaff J.
        • et al.
        A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
        Eur J Cancer. 2013; 49: 1287-1296
        • Escudier B.
        • Bellmunt J.
        • Negrier S.
        • et al.
        Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
        J Clin Oncol. 2010; 28: 2144-2150
        • Rini B.I.
        • Halabi S.
        • Rosenberg J.E.
        • et al.
        Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
        J Clin Oncol. 2010; 28: 2137-2143
        • Rini B.I.
        • Tomita Y.
        • Melichar B.
        • et al.
        Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma.
        Clin Genitourin Cancer. 2016; ([e-pub ahead of print])https://doi.org/10.1016/j.clgc.2016.04.005
        • Motzer R.J.
        • Escudier B.
        • Tomczak P.
        • et al.
        Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
        Lancet Oncol. 2013; 14: 552-562